Plain-English translation of NCT05607095 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment approach called lifileucel (LN-144 or LN-145) for people with advanced melanoma of the eye or certain types of sarcoma. The treatment works by removing immune cells that are already fighting your cancer, growing millions more of them in the laboratory, and then putting them back into your body to attack the cancer more powerfully. This is a personalized approach because the cells come from your own tumor.
These rare cancers are very difficult to treat, and many patients don't respond well to standard therapies. This medication takes advantage of the fact that your body has already started fighting the cancer—by amplifying your own immune system's cancer-fighting cells, doctors hope to give your body a stronger weapon against the disease.
You likely qualify if…
You likely don't qualify if…
First, doctors will perform a surgical procedure to remove a portion of your tumor to harvest immune cells from it. Those cells are then sent to a laboratory where they are grown and multiplied over several weeks. While this process is happening, you may receive additional cancer treatment as needed. Once the cells are ready, you will likely receive chemotherapy to prepare your body, followed by an infusion of your grown immune cells back into your bloodstream. You will then be closely monitored with blood tests and imaging scans to see how well the treatment works and to manage any side effects.
AI-generated summary from trial data · Jul 16, 2026 · Not medical advice
United States